NOX2 and brain immune cells linked to brain damage after head injury
NOX2 drives microglia-dependent neurodegeneration after traumatic brain injury
This work looks at whether blocking a harmful protein called NOX2 in brain immune cells can reduce long-term brain inflammation and damage after a traumatic brain injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11194286 on NIH RePORTER |
What this research studies
Researchers are using experimental brain-injury models and advanced single-cell RNA sequencing to map how specific microglial subtypes behave after traumatic brain injury when NOX2 is removed. They will selectively delete NOX2 in microglia and examine how those cells' gene activity and inflammatory behavior change over time. The team will also test whether temporarily removing and reprogramming microglia reduces chronic inflammation and improves markers linked to memory and motor function. Results will identify cellular signals that could become targets for future treatments.
Who could benefit from this research
Good fit: Adults (21+) who have had moderate-to-severe traumatic brain injury and experience ongoing cognitive or motor problems are the most relevant patient group.
Not a fit: Children, people with only mild concussions, or patients whose symptoms arise from non-inflammatory causes may be less likely to benefit directly from these findings.
Why it matters
Potential benefit: If successful, this could point to new therapies that lower chronic brain inflammation and help preserve memory and motor function after TBI.
How similar studies have performed: Prior animal research from this group and others has shown that NOX2 contributes to chronic microglial toxicity and that temporarily removing microglia can improve outcomes, but these approaches have not yet been validated in people.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Stoica, Bogdan Adrian — University of Maryland Baltimore
- Study coordinator: Stoica, Bogdan Adrian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.